Publications by authors named "Dalia B Wajsbrot"

Claim this Profile
A
Analysis and reporting of pediatric growth and development assessment from clinical trials: overview and challenges.
YounJeong Choi, Nathalie Barbier, Sabine Fürst-Recktenwald, Jingjing Ye, Dalia Ballas Wajsbrot

J Biopharm Stat· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trajectories of Function and Symptom Change in Desvenlafaxine Clinical Trials: Toward Personalized Treatment for Depression.
Sigal Zilcha-Mano, Xuemei Wang, Dalia B Wajsbrot, Matthieu Boucher, Stuart A Fine

J Clin Psychopharmacol· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clustering patients by depression symptoms to predict venlafaxine ER antidepressant efficacy: Individual patient data analysis.
Masaki Kato, Yuko Asami, Dalia B Wajsbrot, Xuemei Wang, Matthieu Boucher

J Psychiatr Res· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictors of functional response and remission with desvenlafaxine 50 mg and 100 mg: a pooled analysis of randomized, placebo-controlled studies in patients with major depressive disorder.
Claudio N Soares, Dalia B Wajsbrot, Matthieu Boucher

CNS Spectr· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of desvenlafaxine versus placebo on MDD symptom clusters: A pooled analysis.
Martin A Katzman, Xuemei Wang, Dalia B Wajsbrot, Matthieu Boucher

J Psychopharmacol· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of venlafaxine extended release in major depressive disorder patients: effect of baseline anxiety symptom severity.
Gavin J Lyndon, Rita Prieto, Dalia B Wajsbrot, Christer Allgulander, Borwin Bandelow

Int Clin Psychopharmacol· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Re: "Desvenlafaxine Versus Placebo in a Fluoxetine-Referenced Study of Children and Adolescents with Major Depressive Disorder: Design, Definitions, and Ongoing Challenges for Child and Adolescent Psychopharmacology Research" by Strawn JR and Croarkin PE (J Child Adolesc Psychopharmacol 2018;28:(5)363).
Karen L Weihs, Dalia B Wajsbrot, Deborah Chiles, Sara Ramaker, Phil Chappell

J Child Adolesc Psychopharmacol· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimization of Methylphenidate Extended-Release Chewable Tablet Dose in Children with ADHD: Open-Label Dose Optimization in a Laboratory Classroom Study.
Sharon B Wigal, Ann Childress, Sally A Berry, Heidi W Belden, Phillip Chappell, Dalia B Wajsbrot

J Child Adolesc Psychopharmacol· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Desvenlafaxine Versus Placebo in the Treatment of Children and Adolescents with Major Depressive Disorder.
Sarah Atkinson, Shannon Lubaczewski, Sara Ramaker, Richard D England, Dalia B Wajsbrot

J Child Adolesc Psychopharmacol· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Desvenlafaxine Versus Placebo in a Fluoxetine-Referenced Study of Children and Adolescents with Major Depressive Disorder.
Karen L Weihs, William Murphy, Richat Abbas, Deborah Chiles, Richard D England, Dalia B Wajsbrot

J Child Adolesc Psychopharmacol· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Speed of Improvement in Symptoms of Depression With Desvenlafaxine 50 mg and 100 mg Compared With Placebo in Patients With Major Depressive Disorder.
Martin A Katzman, Andrew A Nierenberg, Dalia B Wajsbrot, Ellen Meier, Rita Prieto

J Clin Psychopharmacol· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of desvenlafaxine 50 mg and 100 mg on energy and lassitude in patients with major depressive disorder: A pooled analysis.
Raymond W Lam, Dalia B Wajsbrot, Ellen Meier, Elizabeth Pappadopulos, Joan A Mackell

J Psychopharmacol· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An epidemiological study to assess the prevalence of diabetic peripheral neuropathic pain among adults with diabetes attending private and institutional outpatient clinics in South Africa.
Andrew Jacovides, Mampedi Bogoshi, Larry A Distiller, Ehab Y Mahgoub, Mahomed Ka Omar, Dalia B Wajsbrot

J Int Med Res· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunovirologic outcomes with maraviroc combination regimens in patients with a history of past treatment failures and virologic resistance in Brazil: an open-label, multicenter phase 3b study.
Juvencio Furtado, José V Madruga, Eliana L Bicudo, Margareth da Eira, Max I B F Lopes, Dalia B Wajsbrot

AIDS Res Hum Retroviruses· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Radiotherapy for pancreatic cancer].
Eduardo Weltman, Joao Victor Salvajoli, Rodrigo de Morais Hanriot, Flavio Eduardo Prisco, Satiro Nakamura de Oliveira, Dalia Ballas Wajsbrot

Rev Assoc Med Bras (1992)· December 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis